Alzheimer's and Dementia Studies | cannabisMD Research Articles

Alzheimer’s and Dementia Studies

It is estimated that in 2018, 5.7 million people of all ages are living with Alzheimer’s disease in the United States. In fact, 1 in 10 people over the age of 65 have been diagnosed. It is the sixth leading cause of death in America. According to research, these statistics are growing in numbers.

The main characterizations of Alzheimer’s disease include; memory loss, failure to complete tasks, issues with words or writing, changes in personality or mood, poor judgment and trouble understanding.

Studies conducted by California’s Salk Institute in 2017 may have found that with the help of cannabidoids, dementia could potentially be removed from the human brain. Important cannabidoids that get to work include CBD and THC. What is vital to note in relation to targeting Alzheimer’s disease is that it is a failure of inflammatory responses. The immune cells within the brain stop emptying blockages which then become disorientating. It is this inflammation that is center to causing Alzheimer’s disease, and can now be reduced with the use of CBD oil.

Oxygen is released into the brain when there is an inflammation and the greater the inflammation, the worse it is. Vital brain functions, including a person’s memory, begin to deplete when increased amounts of oxygen are released to the cell’s of the brain.

It is currently under examination by scientists and doctors alike, as to whether CBD could help with this certain disease. Since CBD holds anti-inflammatory values and is also an antioxidant, this could help to reduce issues related to oxygen stress.

Patients that have been diagnosed with Alzheimer’s disease usually show a signs of rapid decline of their overall health. Treatment for Alzheimer’s patients is necessary and so the continual study into cannabinoids, especially CBD, will be thorough and ongoing.